Accelerant Holdings (ARX) Stock Price & How to Invest

Accelerant Holdings operates a data-driven risk exchange for specialty insurance. On one side are managing general agents (MGAs), the specialist underwriters who design and sell niche insurance products; on the other are risk capital partners such as insurers, reinsurers, and institutional investors who put up the capital to back those policies. Accelerant sits in the middle, using proprietary technology, data, and machine learning to match risk with capital, share high-fidelity underwriting data, and monitor portfolios. It earns a fixed-percentage, volume-based fee for sourcing, managing, and monitoring the business written through the exchange, which spans more than 500 specialty insurance products across 22 countries. The company reports through three segments: Exchange Services, MGA Operations, and Underwriting, and describes its model as capital-light because it aims to retain only a small share of the premium risk (roughly 9% in 2025) and pass the rest to third-party capital.

In 2025 the exchange handled about $4.19 billion of Exchange Written Premium, up roughly 35% year over year, with revenue rising about 51% to $913 million and adjusted EBITDA up sharply to $282 million. The headline figure was a $1.35 billion net loss, but that stemmed almost entirely from a $1.38 billion non-cash profits interest distribution tied to the IPO rather than from operations. Accelerant listed its Class A shares on the NYSE under ARX on July 24, 2025, raising about $724 million. Momentum carried into 2026: first-quarter revenue rose about 54% year over year to roughly $273 million with adjusted EBITDA up about 69%, and management raised full-year guidance, targeting revenue near $1.02 billion for 2026.

The dominant uncertainty is that the capital-light model is young and unproven across a full insurance cycle. Accelerant still reported a large net loss in 2025, and while it was driven by a one-time non-cash IPO item, the gap between statutory results and adjusted metrics means the reported economics deserve scrutiny. As a marketplace, the business depends on keeping both MGAs and capital partners engaged; if capital providers pull back after a run of claims or if competing carriers and fronting platforms court its MGAs, volumes and fees could suffer. Specialty insurance is inherently cyclical, and a soft pricing market or a spike in catastrophe or liability losses could reduce premium flow and pressure the small share of risk Accelerant does retain. The stock is also newly public with a short trading history and a valuation that already embeds continued rapid growth, so disappointments can move it sharply.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Accelerant Holdings's investor relations page or your broker.

• Exchange Written Premium (FY 2025): ~$4.19 billion, up ~35% year over year
• Revenue (FY 2025 / Q1 2026): ~$913 million FY 2025; ~$273 million in Q1 2026 (up ~54%)
• Adjusted EBITDA: ~$282 million FY 2025; ~$66 million in Q1 2026 (up ~69%)
• Net income (FY 2025): ~$1.35 billion loss, almost all from a ~$1.38 billion non-cash IPO item
• Market cap: ~$3.0 billion (stock ~$13 per share)
• Valuation: ~9x forward (FY 2026) EV/EBITDA

Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Accelerant only listed in July 2025, its trading and reporting history is short, and its large statutory net loss diverges from the adjusted EBITDA it emphasizes, so the two frames tell different stories. The valuation reflects rapid revenue and EBITDA growth rather than current bottom-line profit, meaning the figures matter most as a gauge of how much future growth is already priced in.

There are three common ways to get ARX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ARX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ARX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Accelerant is a fast-growing, fee-based insurance marketplace that channeled about $4.2 billion of specialty premium across its exchange in 2025 while keeping only a small slice of the risk on its own books, and it trades around $13 per share for a roughly $3 billion market cap after its July 2025 IPO. The main driver is adding MGA members and capital partners to the exchange and taking a volume-based fee on the premium that flows through, so the question becomes whether the capital-light story holds up as the business scales and the reported loss narrows toward the strong adjusted profitability management reports.

Whether ARX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARX a buy?, and where the stock could go from here in the ARX stock forecast.

For income investors, whether ARX pays a dividend and how the payout looks is covered in does ARX pay a dividend?